I read with interest the review of transplantation-associated thrombotic microangiopathy (TA-TMA) by Batts and Lazarus in the Bone Marrow Transplantation journal (October 2007; 40: 709-719). There are several important considerations in this article that point to the important role of nitric oxide (NO), the endothelial-derived relaxation factor, as a possible contributor to this devastating condition.
The lack of NO has been recently suggested as an important causative factor in the thrombogenesis of hemolytic diseases including TMA. 1 The excess hemolysis depletes NO due to the high affinity of plasma hemoglobin to the endothelial-derived NO. This deficiency of NO, a compound with potent vasodilatory and platelet antiaggregatory properties, can lead to platelet microthrombi in various organs, including kidneys, central nervous system and heart vessels, leading to the clinical syndrome of TMA.
Abnormalities of the vascular endothelium, rather than the von Willebrand cleaving protease enzyme, ADAMTS13 activity (as in idiopathic or congenital TMA), have been thought to be critical to the pathogenesis of TMA in the peritransplant setting. However, endothelial dysfunction is characterized by diminished endothelial NO levels through several mechanisms, including reduced endothelial NO synthase expression and activity, and rapid removal of NO.
There are several risk factors that can lead to endothelial injury in transplant patients, and GVHD is a common factor in many of them. In an animal model of GVHD, suppression of NO production by NG-methyl-L-arginine was associated with enhanced weight loss early post transplant and decreased overall survival and impaired hematopoietic reconstitution, suggesting a protective role for NO in this complication. 2 In severe GVHD, however, the need for increased production of NO may exhaust the NO synthases and lead to the worsening of GVHD and TMA. In addition, another implicated factor for TMA, calcineurin inhibitors used for GVHD prophylaxis, have been associated with decreased production of prostaglandin-I 2 , which can in turn lead to decreased NO production especially in renal vasculature, although cyclosporine has been shown to directly reduce renal NO synthesis. 3 Wolff et al. 4 describes good response of TMA in 9 of 13 patients with GVHD and TMA who were switched from a calcineurin inhibitor to the anti-CD25 antibody, daclizumab. This antibody, which does not have either an endotoxic or nephrotoxic potential, has shown a high response rate in TA-TMA possibly by not causing or promoting endothelial injury or NO depletion in the kidneys.
Plasma exchange is the treatment of choice in congenital and nontransplant-associated TMA and is thought to replace the deficient ADAMTS-13 and remove the antibodies toward this enzyme. However, this procedure would also remove the RBC-free hemoglobin, thus helping in stopping the removal of NO, which binds to it with high affinity. At the same time, in the peritransplant setting, this strategy is unlikely to be helpful due to the extensive endothelial dysfunction resulting in the continued lack of NO.
The review also mentions the use of newer agents reported to be presently and potentially useful in the management of TA-TMA, many of which would increase the levels of NO. Defibrotide was used initially for these patients because of the similarities between veno-occlusive disease and TA-TMA. Veno-occlusive disease is also associated with reduced levels of NO, and decreased production of this compound has been demonstrated in a rat model of hepatic sinusoidal obstruction syndrome. 5 Defibrotide itself has been shown to increase NO production in two animal heart experiments. In normally perfused hearts of guinea-pig, both defibrotide and its fraction increase the amount of nitrite appearing in perfusates in a concentration-dependent manner. This increase in nitrite and coronary flow were significantly reduced by NGmonomethyl-L-arginine, the inhibitor of NO synthase. 6 Another interesting study demonstrated an increase in prostaglandin-I 2 production caused by defibrotide, which can counterbalance impaired NO generation and attenuate hyperreactivity of the coronary vasculature, indicating that prostaglandin-I 2 production takes part in NO generation. 7 The study of Takatsuka and colleagues mentioned in the article that administered eicosapentaenoic acid starting 3 weeks before unrelated donor allogeneic transplant, until 180 days following transplantation, was successful in preventing any cases of TMA. In this context, it is relevant to note that long-term oral administration of eicosapentaenoic acid has been shown to increase stimulation of NO production in diabetic rats. 8 Rituximab, an anti-CD20 antibody, also has been increasingly used in TMA, although the exact mechanism of action is not well known, and an immunomodulatory effect is suggested. It may be speculated that the release of cytokines, which happens very commonly with the use of this antibody, could possibly stimulate the production of NO and improve the clinical picture.
Statins, drugs widely used for various vascular indications, have been proposed to be useful in TA-TMA and have also been shown to increase NO levels. 9 Another potential therapy in TA-TMA is anti-tumor necrosis factor-a agents. Goodwin et al. 10 recently demonstrated that endothelial dysfunction associated with elevated serum levels of tumor necrosis factor-a observed in diabetes, obesity and congenital heart disease results, in part, from the impaired production of endothelial NO, suggesting anti-tumor necrosis factor-a agents to be possibly helpful in TMA. In summary, NO may play an important role in the pathogenesis of TA-TMA. Different therapeutic strategies may be working in different ways to increase the plasma levels of this compound, and thus proving to be effective in this condition. Although the pathophysiological role of NO in TMA has only recently been recognized and may be extended to TA-TMA, the widespread use of NO donors is not yet common, despite the successful use of a transdermal NO preparation in a patient with transplant-related hemolytic uremic syndrome, reported in the article.
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